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Purpose: To evaluate the significance of fractionated 
administration of thalidomide combined with γ-ray 
irradiation in terms of local tumor response and lung 
metastatic potential, referring to the response of intratumor 
quiescent (Q) cells. 
Materials/methods: B16-BL6 melanoma tumor-bearing 
C57BL/6 mice were continuously given 5-bromo-2’-
deoxyuridine (BrdU) to label all proliferating (P) cells. The 
tumor-bearing mice then received γ-ray irradiation after 
thalidomide treatment through a single or 2 consecutive daily 
intraperitoneal administrations up to a total dose of 400 
mg/kg in combination with an acute hypoxia-releasing agent 
(nicotinamide, 1,000 mg/kg, intraperitoneally administered) 
or mild temperature hyperthermia (MTH, 40 centigrade for 
60 minutes). Immediately after the irradiation, cells from 
some tumors were isolated and incubated with a cytokinesis 
blocker. The responses of the Q and total (= P + Q) cell 
populations were assessed based on the frequency of 
micronuclei using immunofluorescence staining for BrdU. In 
other tumor-bearing mice, 17 days after irradiation, 
macroscopic lung metastases were enumerated. 
Results: Thalidomide raised the sensitivity of the total cell 
population more remarkably than Q cells in both single and 
daily administrations. Daily administration of thalidomide 
elevated the sensitivity of both the total and Q cell 
populations, but especially the total cell population, 
compared with single administration. Daily administration, 
especially combined with MTH, decreased the number of lung 
metastases. 
Conclusions: Daily fractionated administration of thalidomide 
in combination with γ-ray irradiation was thought to be more 
promising than single administration because of its potential 
to enhance local tumor response and repress lung metastatic 
potential. 
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Purpose: The Malthus model is an evidence based simulation 
of radiotherapy demand in England, which was designed to 
estimate radiotherapy utilisation at local and national level, 
in order to assist in planning of radiotherapy services. The 
model utilised cancer registration data from the national 
cancer registration service, together with predictions of 
population growth from the Office of National Statistics, and 
cancer incidence projections. We present the results of an 
updated model that utilises the latest population projection 
estimates, and cancer incidence data. 
Materials and Methods: Base data on cancer registration was 
provided by the National Cancer Intelligence Network, 
broken down by disease site, local Clinical Commissioning 
Groups (CCGs), age and sex. Equivalent population data was 
sourced from the Office for National Statistics. These two 
datasets were combined with data from 2,000 evidence-
based clinical decisions, covering 22 different cancer sites. 
Clinical practice was peer-reviewed by over 100 British 
oncologists and at a national forum. An updated cancer 
incidence projection model and population projection model 
were also used to enable annual demand predictions up to 
2035. 
Results: The Malthus model estimates that the access rate for 
radiotherapy in England in 2015 should be 40.5% with a 
fraction burden of approximately 47,500 fractions per million 
population. To highlight how different regions within a 
country can be, Table 1 displays two regions and the England 
average for comparison. The predicted demand for 
radiotherapy is also increasing for England. Over the next few 
year the predicted fractions per million will increase by 0.9% 
per year, this will increase to 1% per year in 2020 and is 
expected to hit 1.1% per year by 2026.  
 
 
 
Conclusions: The Malthus model with updated cancer 
incidence data suggests a radiotherapy utilisation rate of 
40.5%, with a predicted annual increase of fractions per 
million of around 1% per year. Whilst the observed rates of 
radiotherapy utilisation still lag behind the model’s 
predictions, the observed activity increases in England (from 
the Radiotherapy Data Set) over the last 3 years exceed the 
rate of rise in predicted demand. Customised simulations for 
individual regions, such as what Malthus can do, allows local 
cancer profiles to be taken into account for more accurate 
current and future demand predictions. The customisability 
also allows for simulations looking at the impact of new 
technology, such as MRI Linac and Proton therapy, and data 
from other countries can be incorporated as well.  
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Purpose: MRI-linacs will enable 4D image-guided radiotherapy 
and require accurate MR visible and compatible dosimeter 
systems for verification. 
Methods: Motion-tracking utilising a MagicPlate (M512) silicon 
array dosimeter capable of high resolution dosimetry 
(Petasecca, 2015) (figure 1a,b)has been modified for purpose 
of MR imaging during dynamic detector-tracking (i.e. so 
named ‘MR guided dynamic dosimaging’). The detector was 
tested for MRI-safety and functionality without irradiation in 
a 1T fringe field of 3T Siemens Skyra MRI. As solid water can 
not be visualized on MRI a tissue-equivalent, gel-water 
phantom (CIRS® Computerized Imaging Reference Systems 
Inc. VA, USA), providing signal for detector and fiducial 
visualisation, was utilised to enable MR imaging (fast spin 
echo sequence).  
Results: MR images of a non-powered detector system 
demonstrated detector visualization (see figure 1c). Detector 
movements approximating breathing were also acquired 
during dynamic MRI acquisition (fast gradient echo), showing 
that fiducial markers could be visualised when placed on a 
passive device and tracked. The detector functioned at the 
1T bore entry position to simulate the magnetic field of our 
impending MR linac whilst a water phantom was imaged 
simultaneously at the mid-bore 3T position, with noise (see 
figure 1d) seen due to detector RF interference being 
reduced by aluminium foil shielding of the device and cables 
(figure 1e).  
Conclusions: The current MRI-guided dynamic dosimaging set-
up has been demonstrated to be successful in detector 
visualisation and tracking with a non-powered detector. 
Noise reduction has been achieved with the detector in 
operational mode. A MRI-compatible motion platform will be 
paired with M512. These measurements will be compared to 
acquisition in MRI-linac magnetic fields on the MRI-linac 
device being installed at the Ingham Institute in Australia. 
 
Keywords: Radiotherapy, MRI-linac, dosimetry 
 
References: 
Petasecca, M. et al (2015), Med Phys, 42(6):2992-3004. 
 
